Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Eskaylab Limited, headquartered in Great Britain, is a prominent player in the biotechnology industry, specialising in innovative laboratory services and solutions. Founded in 2010, the company has rapidly established itself as a leader in the development of advanced analytical techniques and bespoke research services, catering to a diverse range of sectors including pharmaceuticals, environmental science, and food safety.
With a commitment to quality and precision, Eskaylab Limited offers unique core services such as custom assay development and comprehensive data analysis, setting them apart from competitors. The company has achieved significant milestones, including partnerships with leading research institutions and recognition for its contributions to scientific advancements. As a trusted name in the industry, Eskaylab Limited continues to drive innovation and excellence in laboratory services across the UK and beyond.
+64 vs industry average
Eskaylab Limited’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Business Services has below-average carbon intensity
The Business Services industry has reduced its overall emissions by 25% since 2018
No reported emissions data is available for Eskaylab Limited yet.
Eskaylab Limited, headquartered in Great Britain, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of GSK plc, and any climate commitments or initiatives are likely influenced by GSK's sustainability strategies.
Eskaylab Limited's climate commitments are cascaded from GSK plc, which has established various initiatives aimed at reducing carbon emissions across its operations. These initiatives include targets set under the Science Based Targets initiative (SBTi), participation in the Carbon Disclosure Project (CDP), and commitments to renewable energy through the RE100 initiative. GSK plc's climate strategies are designed to align with global climate goals, although specific reduction targets for Eskaylab Limited have not been disclosed.
As a subsidiary, Eskaylab Limited is expected to adhere to the sustainability practices and performance metrics established by GSK plc, which may include significant reductions in Scope 1, 2, and 3 emissions as part of their overarching climate strategy. However, without specific emissions data or reduction targets available for Eskaylab Limited, the details of their individual commitments remain unclear.
No climate goals have been disclosed for Eskaylab Limited yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Eskaylab Limited yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more